+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study

The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study

Anesthesia and Analgesia 105(6): 1540-7

BACKGROUND: The benefit-risk ratio of extended fondaparinux therapy has not been assessed in patients undergoing major lower limb joint arthroplasty. Few data on the concomitant use of fondaparinux and continuous neuraxial or deep peripheral nerve blockade are available. We performed a prospective intervention study in patients undergoing major orthopedic surgery primarily designed to assess the efficacy of fondaparinux when drug administration was withheld for 48 h to pen-rut removal of a neuraxial or deep peripheral nerve catheter. The safety and efficacy of extended fonclaparinux therapy for the prevention of venous thromboembolism were also evaluated.METHODS: Patients received a daily subcutaneous injection of 2.5 mg fondaparinux for 3 to 5 wk postoperatively. In patients with a neuraxial or deep peripheral nerve catheter, the catheter was removed 36 h after the last fondaparinux dose. The next fondaparinux dose was administered 12 h after catheter removal. The primary end points were symptomatic venous thromboembolism and major bleeding up to 4-6 wk after surgery.RESULTS: We recruited 5704 patients. A neuraxial or deep peripheral nerve catheter was inserted in 1553 (27%) patients and 78 (1.4%) patients, respectively. The rate of venous thromboembolism was 1.0% (54 of 5387). There was no difference between patients without (1.1%) or with (0.8%) a catheter (the upper limit of the 95% confidence interval of the odds ratio, 1.49, being below the predetermined noninferiority margin of 1.75). The incidence of major bleeding was 0.8% (42 of 5382). No neuraxial or perineural hematoma was reported.CONCLUSIONS: Once-daily subcutaneous injection of 2.5 mg fondaparinux given for 3 to 5 wk was effective and safe for prevention of venous thromboembolism after major orthopedic surgery. Temporary discontinuation of fondaparinux for 48 h permitted safe removal of a neuraxial or deep peripheral nerve catheter without decreasing thromboprophylatic efficacy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 021983405

Download citation: RISBibTeXText

PMID: 18042845

DOI: 10.1213/01.ane.0000287677.95626.60

Related references

Use of neuraxial catheter for anaesthesia/analgesia in major orthopedic lower limb surgery patients treated with prophylactic doses of fondaparinux (Arixtra) in routine practice:the expert study. Regional Anesthesia and Pain Medicine 30(5): 12-12, 2005

Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopaedic surgery – findings from the ortho-tep registry. 2012

Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thrombosis and Haemostasis 90(2): 364-366, 2003

Effect of Age on the Benefit-Risk Ratio of Fondaparinux Thromboprophylaxis in Patients Undergoing Major Orthopedic Surgery. Blood 100(11): Abstract No 1066, 2002

Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opinion on Drug Safety 10(5): 687-696, 2011

Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. Thrombosis Journal 9: 17-17, 2011

Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest 126(2): 501-508, 2004

Wound/intra-articular infiltration or peripheral nerve blocks for orthopedic joint surgery: efficacy and safety issues. Current Opinion in Anaesthesiology 25(5): 615-620, 2012

Neuraxial and Combined Neuraxial/General Anesthesia Compared to General Anesthesia for Major Truncal and Lower Limb Surgery: A Systematic Review and Meta-analysis. Anesthesia and Analgesia 125(6): 1931-1945, 2017

Safety, efficacy and compliance of extended thromboprophylaxis in hepatobiliary and upper gastrointestinal surgery. Anz Journal of Surgery 89(4): 357-361, 2019

Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis. British Journal of Clinical Pharmacology 84(10): 2242-2251, 2018

Early diagnosis of lower limb deep vein thrombosis after major orthopedic surgeries. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 24(6): 730-734, 2010

Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery. Thrombosis and Haemostasis 94(3): 532-536, 2005

The efficacy and safety of epidural dexmedetomidine and clonidine with bupivacaine in patients undergoing lower limb orthopedic surgeries. Journal of Anaesthesiology Clinical Pharmacology 32(2): 203-209, 2016

The impact of peripheral nerve techniques on hospital stay following major orthopedic surgery. Pain Medicine 13(6): 828-834, 2013